EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†: Annals of oncology : official journal of the European Society for Medical Oncology

A Horwich; M Babjuk; J Bellmunt; HM Bruins; TMD Reijke; MD Santis; S Gillessen; N James; S Maclennan; J Palou; T Powles; MJ Ribal; SF Shariat; TVD Kwast; E Xylinas; N Agarwal; T Arends; A Bamias; A Birtle; PC Black; BH Bochner; M Bolla; JL Boormans; A Bossi; A Briganti; I Brummelhuis; M Burger; D Castellano; R Cathomas; A Chiti; A Choudhury; E Compérat; S Crabb; S Culine; BD Bari; WD Blok; PJL De Visschere; K Decaestecker; K Dimitropoulos; JL Dominguez-Escrig; S Fanti; V Fonteyne; M Frydenberg; JJ Futterer; G Gakis; B Geavlete; P Gontero; B Grubmüller; S Hafeez; DE Hansel; A Hartmann; D Hayne; AM Henry; V Hernandez; H Herr; K Herrmann; P Hoskin; J Huguet; BA Jereczek-Fossa; R Jones; AM Kamat; V Khoo; AE Kiltie; S Krege; S Ladoire; PC Lara; A Leliveld; E Linares-Espinós; V Løgager; A Lorch; Y Loriot; R Meijer; MC Mir; M Moschini; H Mostafid; AC Müller; CR Müller; J N'Dow; A Necchi; Y Neuzillet; JR Oddens; J Oldenburg; S Osanto; WJG Oyen; L Pacheco-Figueiredo; H Pappot; MI Patel; BR Pieters; K Plass; M Remzi; M Retz; J Richenberg; M Rink; F Roghmann; JE Rosenberg; M Rouprêt; O Rouvière; C Salembier; A Salminen; P Sargos

doi:10.1093/annonc/mdz296

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†: Annals of oncology : official journal of the European Society for Medical Oncology

A Horwich, M Babjuk, J Bellmunt, HM Bruins, TMD Reijke, MD Santis, S Gillessen, N James, S Maclennan, J Palou, T Powles, MJ Ribal, SF Shariat, TVD Kwast, E Xylinas, N Agarwal, T Arends, A Bamias, A Birtle, PC BlackBH Bochner, M Bolla, JL Boormans, A Bossi, A Briganti, I Brummelhuis, M Burger, D Castellano, R Cathomas, A Chiti, A Choudhury, E Compérat, S Crabb, S Culine, BD Bari, WD Blok, PJL De Visschere, K Decaestecker, K Dimitropoulos, JL Dominguez-Escrig, S Fanti, V Fonteyne, M Frydenberg, JJ Futterer, G Gakis, B Geavlete, P Gontero, B Grubmüller, S Hafeez, DE Hansel, A Hartmann, D Hayne, AM Henry, V Hernandez, H Herr, K Herrmann, P Hoskin, J Huguet, BA Jereczek-Fossa, R Jones, AM Kamat, V Khoo, AE Kiltie, S Krege, S Ladoire, PC Lara, A Leliveld, E Linares-Espinós, V Løgager, A Lorch, Y Loriot, R Meijer, MC Mir, M Moschini, H Mostafid, AC Müller, CR Müller, J N'Dow, A Necchi, Y Neuzillet, JR Oddens, J Oldenburg, S Osanto, WJG Oyen, L Pacheco-Figueiredo, H Pappot, MI Patel, BR Pieters, K Plass, M Remzi, M Retz, J Richenberg, M Rink, F Roghmann, JE Rosenberg, M Rouprêt, O Rouvière, C Salembier, A Salminen, P Sargos

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. SETTING: Online Delphi survey and consensus conference. PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach. © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Original language	English
Pages (from-to)	1697-1727
Number of pages	31
Journal	Annals of Oncology
Volume	30
Issue number	11
DOIs	https://doi.org/10.1093/annonc/mdz296
Publication status	Published - 2019

Access to Document

10.1093/annonc/mdz296

http://www.scopus.com/inward/record.url?scp=85077175940&partnerID=8YFLogxK

Fingerprint

Dive into the research topics of 'EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†: Annals of oncology : official journal of the European Society for Medical Oncology'. Together they form a unique fingerprint.

Cite this

Horwich, A., Babjuk, M., Bellmunt, J., Bruins, HM., Reijke, TMD., Santis, MD., Gillessen, S., James, N., Maclennan, S., Palou, J., Powles, T., Ribal, MJ., Shariat, SF., Kwast, TVD., Xylinas, E., Agarwal, N., Arends, T., Bamias, A., Birtle, A., ... Sargos, P. (2019). EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†: Annals of oncology : official journal of the European Society for Medical Oncology. Annals of Oncology, 30(11), 1697-1727. https://doi.org/10.1093/annonc/mdz296

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees† : Annals of oncology : official journal of the European Society for Medical Oncology. / Horwich, A; Babjuk, M; Bellmunt, J; Bruins, HM; Reijke, TMD; Santis, MD; Gillessen, S; James, N; Maclennan, S; Palou, J; Powles, T; Ribal, MJ; Shariat, SF; Kwast, TVD; Xylinas, E; Agarwal, N; Arends, T; Bamias, A; Birtle, A; Black, PC; Bochner, BH; Bolla, M; Boormans, JL; Bossi, A; Briganti, A; Brummelhuis, I; Burger, M; Castellano, D; Cathomas, R; Chiti, A; Choudhury, A; Compérat, E; Crabb, S; Culine, S; Bari, BD; Blok, WD; De Visschere, PJL; Decaestecker, K; Dimitropoulos, K; Dominguez-Escrig, JL; Fanti, S; Fonteyne, V; Frydenberg, M; Futterer, JJ; Gakis, G; Geavlete, B; Gontero, P; Grubmüller, B; Hafeez, S; Hansel, DE; Hartmann, A; Hayne, D; Henry, AM; Hernandez, V; Herr, H; Herrmann, K; Hoskin, P; Huguet, J; Jereczek-Fossa, BA; Jones, R; Kamat, AM; Khoo, V; Kiltie, AE; Krege, S; Ladoire, S; Lara, PC; Leliveld, A; Linares-Espinós, E; Løgager, V; Lorch, A; Loriot, Y; Meijer, R; Mir, MC; Moschini, M; Mostafid, H; Müller, AC; Müller, CR; N'Dow, J; Necchi, A; Neuzillet, Y; Oddens, JR; Oldenburg, J; Osanto, S; Oyen, WJG; Pacheco-Figueiredo, L; Pappot, H; Patel, MI; Pieters, BR; Plass, K; Remzi, M; Retz, M; Richenberg, J; Rink, M; Roghmann, F; Rosenberg, JE; Rouprêt, M; Rouvière, O; Salembier, C; Salminen, A; Sargos, P.

In: Annals of Oncology, Vol. 30, No. 11, 2019, p. 1697-1727.

Research output: Contribution to journal › Article › peer-review

Horwich, A, Babjuk, M, Bellmunt, J, Bruins, HM, Reijke, TMD, Santis, MD, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, MJ, Shariat, SF, Kwast, TVD, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, PC, Bochner, BH, Bolla, M, Boormans, JL, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Compérat, E, Crabb, S, Culine, S, Bari, BD, Blok, WD, De Visschere, PJL, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, JL, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, JJ, Gakis, G, Geavlete, B, Gontero, P, Grubmüller, B, Hafeez, S, Hansel, DE, Hartmann, A, Hayne, D, Henry, AM, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, BA, Jones, R, Kamat, AM, Khoo, V, Kiltie, AE, Krege, S, Ladoire, S, Lara, PC, Leliveld, A, Linares-Espinós, E, Løgager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, MC, Moschini, M, Mostafid, H, Müller, AC, Müller, CR, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, JR, Oldenburg, J, Osanto, S, Oyen, WJG, Pacheco-Figueiredo, L, Pappot, H, Patel, MI, Pieters, BR, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, JE, Rouprêt, M, Rouvière, O, Salembier, C, Salminen, A & Sargos, P 2019, 'EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†: Annals of oncology : official journal of the European Society for Medical Oncology', Annals of Oncology, vol. 30, no. 11, pp. 1697-1727. https://doi.org/10.1093/annonc/mdz296

Horwich A, Babjuk M, Bellmunt J, Bruins HM, Reijke TMD, Santis MD et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†: Annals of oncology : official journal of the European Society for Medical Oncology. Annals of Oncology. 2019;30(11):1697-1727. https://doi.org/10.1093/annonc/mdz296

Horwich, A ; Babjuk, M ; Bellmunt, J ; Bruins, HM ; Reijke, TMD ; Santis, MD ; Gillessen, S ; James, N ; Maclennan, S ; Palou, J ; Powles, T ; Ribal, MJ ; Shariat, SF ; Kwast, TVD ; Xylinas, E ; Agarwal, N ; Arends, T ; Bamias, A ; Birtle, A ; Black, PC ; Bochner, BH ; Bolla, M ; Boormans, JL ; Bossi, A ; Briganti, A ; Brummelhuis, I ; Burger, M ; Castellano, D ; Cathomas, R ; Chiti, A ; Choudhury, A ; Compérat, E ; Crabb, S ; Culine, S ; Bari, BD ; Blok, WD ; De Visschere, PJL ; Decaestecker, K ; Dimitropoulos, K ; Dominguez-Escrig, JL ; Fanti, S ; Fonteyne, V ; Frydenberg, M ; Futterer, JJ ; Gakis, G ; Geavlete, B ; Gontero, P ; Grubmüller, B ; Hafeez, S ; Hansel, DE ; Hartmann, A ; Hayne, D ; Henry, AM ; Hernandez, V ; Herr, H ; Herrmann, K ; Hoskin, P ; Huguet, J ; Jereczek-Fossa, BA ; Jones, R ; Kamat, AM ; Khoo, V ; Kiltie, AE ; Krege, S ; Ladoire, S ; Lara, PC ; Leliveld, A ; Linares-Espinós, E ; Løgager, V ; Lorch, A ; Loriot, Y ; Meijer, R ; Mir, MC ; Moschini, M ; Mostafid, H ; Müller, AC ; Müller, CR ; N'Dow, J ; Necchi, A ; Neuzillet, Y ; Oddens, JR ; Oldenburg, J ; Osanto, S ; Oyen, WJG ; Pacheco-Figueiredo, L ; Pappot, H ; Patel, MI ; Pieters, BR ; Plass, K ; Remzi, M ; Retz, M ; Richenberg, J ; Rink, M ; Roghmann, F ; Rosenberg, JE ; Rouprêt, M ; Rouvière, O ; Salembier, C ; Salminen, A ; Sargos, P. / EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees† : Annals of oncology : official journal of the European Society for Medical Oncology. In: Annals of Oncology. 2019 ; Vol. 30, No. 11. pp. 1697-1727.

@article{9fa0a946c0b14946a86a1ca7c9d32881,

title = "EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†: Annals of oncology : official journal of the European Society for Medical Oncology",

abstract = "BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. SETTING: Online Delphi survey and consensus conference. PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach. {\textcopyright} The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.",

author = "A Horwich and M Babjuk and J Bellmunt and HM Bruins and TMD Reijke and MD Santis and S Gillessen and N James and S Maclennan and J Palou and T Powles and MJ Ribal and SF Shariat and TVD Kwast and E Xylinas and N Agarwal and T Arends and A Bamias and A Birtle and PC Black and BH Bochner and M Bolla and JL Boormans and A Bossi and A Briganti and I Brummelhuis and M Burger and D Castellano and R Cathomas and A Chiti and A Choudhury and E Comp{\'e}rat and S Crabb and S Culine and BD Bari and WD Blok and {De Visschere}, PJL and K Decaestecker and K Dimitropoulos and JL Dominguez-Escrig and S Fanti and V Fonteyne and M Frydenberg and JJ Futterer and G Gakis and B Geavlete and P Gontero and B Grubm{\"u}ller and S Hafeez and DE Hansel and A Hartmann and D Hayne and AM Henry and V Hernandez and H Herr and K Herrmann and P Hoskin and J Huguet and BA Jereczek-Fossa and R Jones and AM Kamat and V Khoo and AE Kiltie and S Krege and S Ladoire and PC Lara and A Leliveld and E Linares-Espin{\'o}s and V L{\o}gager and A Lorch and Y Loriot and R Meijer and MC Mir and M Moschini and H Mostafid and AC M{\"u}ller and CR M{\"u}ller and J N'Dow and A Necchi and Y Neuzillet and JR Oddens and J Oldenburg and S Osanto and WJG Oyen and L Pacheco-Figueiredo and H Pappot and MI Patel and BR Pieters and K Plass and M Remzi and M Retz and J Richenberg and M Rink and F Roghmann and JE Rosenberg and M Roupr{\^e}t and O Rouvi{\`e}re and C Salembier and A Salminen and P Sargos",

year = "2019",

doi = "10.1093/annonc/mdz296",

language = "English",

volume = "30",

pages = "1697--1727",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

number = "11",

}

TY - JOUR

T1 - EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†

T2 - Annals of oncology : official journal of the European Society for Medical Oncology

AU - Horwich, A

AU - Babjuk, M

AU - Bellmunt, J

AU - Bruins, HM

AU - Reijke, TMD

AU - Santis, MD

AU - Gillessen, S

AU - James, N

AU - Maclennan, S

AU - Palou, J

AU - Powles, T

AU - Ribal, MJ

AU - Shariat, SF

AU - Kwast, TVD

AU - Xylinas, E

AU - Agarwal, N

AU - Arends, T

AU - Bamias, A

AU - Birtle, A

AU - Black, PC

AU - Bochner, BH

AU - Bolla, M

AU - Boormans, JL

AU - Bossi, A

AU - Briganti, A

AU - Brummelhuis, I

AU - Burger, M

AU - Castellano, D

AU - Cathomas, R

AU - Chiti, A

AU - Choudhury, A

AU - Compérat, E

AU - Crabb, S

AU - Culine, S

AU - Bari, BD

AU - Blok, WD

AU - De Visschere, PJL

AU - Decaestecker, K

AU - Dimitropoulos, K

AU - Dominguez-Escrig, JL

AU - Fanti, S

AU - Fonteyne, V

AU - Frydenberg, M

AU - Futterer, JJ

AU - Gakis, G

AU - Geavlete, B

AU - Gontero, P

AU - Grubmüller, B

AU - Hafeez, S

AU - Hansel, DE

AU - Hartmann, A

AU - Hayne, D

AU - Henry, AM

AU - Hernandez, V

AU - Herr, H

AU - Herrmann, K

AU - Hoskin, P

AU - Huguet, J

AU - Jereczek-Fossa, BA

AU - Jones, R

AU - Kamat, AM

AU - Khoo, V

AU - Kiltie, AE

AU - Krege, S

AU - Ladoire, S

AU - Lara, PC

AU - Leliveld, A

AU - Linares-Espinós, E

AU - Løgager, V

AU - Lorch, A

AU - Loriot, Y

AU - Meijer, R

AU - Mir, MC

AU - Moschini, M

AU - Mostafid, H

AU - Müller, AC

AU - Müller, CR

AU - N'Dow, J

AU - Necchi, A

AU - Neuzillet, Y

AU - Oddens, JR

AU - Oldenburg, J

AU - Osanto, S

AU - Oyen, WJG

AU - Pacheco-Figueiredo, L

AU - Pappot, H

AU - Patel, MI

AU - Pieters, BR

AU - Plass, K

AU - Remzi, M

AU - Retz, M

AU - Richenberg, J

AU - Rink, M

AU - Roghmann, F

AU - Rosenberg, JE

AU - Rouprêt, M

AU - Rouvière, O

AU - Salembier, C

AU - Salminen, A

AU - Sargos, P

PY - 2019

Y1 - 2019

N2 - BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. SETTING: Online Delphi survey and consensus conference. PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach. © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

AB - BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. SETTING: Online Delphi survey and consensus conference. PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach. © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

U2 - 10.1093/annonc/mdz296

DO - 10.1093/annonc/mdz296

M3 - Article

VL - 30

SP - 1697

EP - 1727

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -